Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Solving Solubility Challenges for a Novel Oncology Drug | Contract Pharma

What are you searching for?

Sign in
Sponsored Content

Solving Solubility Challenges for a Novel Oncology Drug

Learn how Lubrizol Life Science Health solved bioavailability challenges and scaled a commercially viable formulation of a new cancer treatment.

Released By Lubrizol Life Science Health

Poor aqueous solubility and bioavailability are common challenges for oncology drugs, affecting up to 90% of new chemical entities (NCEs). Finding a scalable approach to solving these issues is critical to achieving clinical efficacy and taking a new drug to market.


Iterion Therapeutics, a clinical stage biotechnology company, is dedicated to developing novel cancer therapeutics for a broad range of cancers. When Iterion’s lead product, Tegavivint, demonstrated low solubility in water, they needed a partner who could not only solve their bioavailability challenges, but also develop a scalable formulation with a viable manufacturing strategy. They turned to the experts at Lubrizol Life Science Health (LLS Health).


In this case study, you’ll learn how LLS Health combined its nanomilling expertise and GMP manufacturing capabilities to maximize bioavailability, improve patient experience, and take Iterion’s poorly soluble compound into clinical studies. 

 

DOWNLOAD THE FULL CASE STUDY TO LEARN MORE >>>>>


 

Download Sponsored Content Now

Download Sponsored Content Now

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics